AxoGen, Inc. Appoints Angelo G. Scopelianos, Ph.D. as Vice President, Research and Development
September 04 2018 - 7:00AM
AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for damage or discontinuity
to peripheral nerves, today announced the appointment of Angelo G.
Scopelianos, Ph.D., to the newly created position of Vice
President, Research and Development, effective immediately. In this
new role he will lead the company’s research and product
development strategies, focused on developing next generation
peripheral nerve repair products.
“We are excited to welcome Dr. Scopelianos to the
team,” commented Karen Zaderej, chairman, CEO, and president of
AxoGen. “His innovative research and product development work spans
medical devices, biomaterials, drug device combinations, and
regenerative medicine. I am confident the depth and breadth of his
experience will further enhance our R&D capabilities as we
continue to create and develop our expanding platform for nerve
repair.”
Prior to joining AxoGen, Dr. Scopelianos was an
independent consultant specializing in medical devices. He began
consulting after a 24-year career at Johnson & Johnson. As
Senior Vice President of Research and Development he led a world
class corporate team comprised of multidisciplinary scientists,
engineers, and medical doctors responsible for developing a wide
range of life-enhancing products and technologies across the
company’s medical device, pharmaceutical, and consumer
organizations. He joined Johnson & Johnson after research
leadership positions at EI Dupont de Nemours in Wilmington,
Delaware and Pennwalt Corporation.
Dr. Scopelianos received his doctorate degree in
Organic Chemistry from Pennsylvania State University, following
completion of a Bachelor of Science degree from the State
University of New York – Oneonta. He holds over 35 U.S.
patents and numerous international patents and his awards include
the Outstanding Science Alumni Award by Pennsylvania State
University; the Scientific Leadership Award in Biomaterials Science
awarded by a consortium of NJ research universities: Rutgers
University, Princeton University & NJ Institute of
Technology; the Johnson & Johnson Philip B. Hofmann Award
for technical achievements in scientific research; and Honorary
Doctor of Science Degree bestowed by the State University of New
York.
“AxoGen represents a compelling opportunity to
apply my passion for developing revolutionary products aimed at
improving patient quality of life,” said Scopelianos. “I look
forward to working with the AxoGen team to develop additional
surgical solutions that address unmet needs in the repair of
peripheral nerves.”
About AxoGenAxoGen (AXGN) is the
leading company focused specifically on the science, development
and commercialization of technologies for peripheral nerve
regeneration and repair. We are passionate about helping to restore
peripheral nerve function and quality of life to patients with
physical damage or discontinuity to peripheral nerves by providing
innovative, clinically proven and economically effective repair
solutions for surgeons and health care providers. Peripheral nerves
provide the pathways for both motor and sensory signals throughout
the body. Every day, people suffer traumatic injuries or undergo
surgical procedures that impact the function of their peripheral
nerves. Physical damage to a peripheral nerve, or the
inability to properly reconnect peripheral nerves, can result in
the loss of muscle or organ function, the loss of sensory feeling,
or the initiation of pain.
AxoGen's platform for peripheral nerve repair
features a comprehensive portfolio of products, including Avance®
Nerve Graft, an off-the-shelf processed human nerve allograft for
bridging severed peripheral nerves without the comorbidities
associated with a second surgical site; AxoGuard® Nerve Connector,
a porcine submucosa extracellular matrix (ECM) coaptation aid for
tensionless repair of severed peripheral nerves; AxoGuard® Nerve
Protector, a porcine submucosa ECM product used to wrap and protect
damaged peripheral nerves and reinforce the nerve reconstruction
while preventing soft tissue attachments; and Avive® Soft
Tissue Membrane, a minimally processed human umbilical cord
membrane that may be used as a resorbable soft tissue covering to
separate tissue layers and modulate inflammation in the surgical
bed. Along with these core surgical products, AxoGen also offers
AcroVal® Neurosensory & Motor Testing System and AxoTouch®
Two-Point Discriminator. These evaluation and measurement tools
assist health care professionals in detecting changes in sensation,
assessing return of sensory, grip, and pinch function, evaluating
effective treatment interventions, and providing feedback to
patients on peripheral nerve function. The AxoGen portfolio of
products is available in the United States, Canada, the United
Kingdom, and several other European and international
countries.
Cautionary Statements Concerning
Forward-Looking Statements This Press Release contains
“forward-looking” statements as defined in the Private Securities
Litigation Reform Act of 1995. These statements are based on
management's current expectations or predictions of future
conditions, events, or results based on various assumptions and
management's estimates of trends and economic factors in the
markets in which we are active, as well as our business plans.
Words such as “expects,” “anticipates,” “intends,” “plans,”
“believes,” “seeks,” “estimates,” “projects,” “forecasts,”
“continue,” “may,” “should,” “will,” and variations of such words
and similar expressions are intended to identify such
forward-looking statements. The forward-looking statements may
include, without limitation, statements regarding our assessment on
our internal control over financial reporting, our growth, our 2018
guidance, product development, product potential, financial
performance, sales growth, product adoption, market awareness of
our products, data validation, our visibility at and sponsorship of
conferences and educational events. The forward-looking statements
are subject to risks and uncertainties, which may cause results to
differ materially from those set forth in the statements.
Forward-looking statements in this release should be evaluated
together with the many uncertainties that affect AxoGen's business
and its market, particularly those discussed in the risk factors
and cautionary statements in AxoGen's filings with the Securities
and Exchange Commission. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those projected. The forward-looking statements are
representative only as of the date they are made and, except as
required by law, AxoGen assumes no responsibility to update any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:AxoGen, Inc. Kaila
Krum, VP, Investor Relations and Corporate Development
kkrum@AxoGenInc.com
Solebury Trout Brian Korb 646.378.2923
bkorb@troutgroup.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2023 to Apr 2024